Stifel initiated coverage of Soleno Therapeutics with a Buy rating and $63 price target. Soleno, after “many adversities,” has a de-risked asset in diazoxide choline controlled-release, or DCCR, that may gain the first regulatory approval in Prader-Willi syndrome, or PWS, the analyst tells investors. While noting that Soleno faces regulatory and commercial risks ahead of potential regulatory submission(s) by mid-2024, the firm sees a “potential blockbuster opportunity” given the high unmet need in PWS and several high profile failures in the past, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLNO:
- Soleno Therapeutics announces inducement grants under Nasdaq listing rule
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics files automatic mixed securities shelf
- Soleno Therapeutics price target raised to $47 from $44 at Oppenheimer
- Best-Performing Stocks of 2023: Can They Keep On Rolling?
